Douglas Beach, MD
Hematology & Oncology · Philadelphia, PANPI 1457598930
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by AstraZeneca at 41.5% of the total. Reporting peaked in 2023 at $2,186 and has fallen 94.1% since, to $129 in 2025.
Across 32 payments — averaging $146.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Astrazeneca UK Limited$2K
- TG Therapeutics, Inc.$467
- Genmab U.S., Inc.$283
- Servier Pharmaceuticals LLC$159
- Abbott$79
- plus $238 from 6 others
Across 58 payments — averaging $5644.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- TG Therapeutics, Inc.$188K
- Genentech, Inc.$70K
- AbbVie$62K
- Amgen$7K
What the payments were for
- Consulting fees$2,39351%
- Travel & lodging$1,16325%
- Food & beverage$96121%
- Education$1593%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $1,943 |
| Astrazeneca UK Limited | 13 | $1,507 |
| TG Therapeutics, Inc. | 2 | $467 |
| Genmab U.S., Inc. | 3 | $283 |
| Servier Pharmaceuticals LLC | 4 | $159 |
| Abbott | 1 | $79 |
| Novartis | 1 | $75 |
| Janssen Scientific Affairs, LLC | 2 | $57 |
| Medtronic | 2 | $36 |
| GSK | 1 | $35 |
| Merck | 1 | $20 |
| Chiesi USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,676 in reported general payments places this provider in the 65th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 23 | $322,502 |
| BrukinsaZanubrutinib | 14 | $214,394 |
| Lenalidomide | 16 | $213,838 |
| XtandiEnzalutamide | 12 | $167,533 |
| EliquisApixaban | 43 | $40,227 |
| XareltoRivaroxaban | 28 | $27,390 |
| Xtampza ErOxycodone Myristate | 13 | $8,629 |
| Oxycodone Hcl | 61 | $1,677 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $1,517 |
| Diclofenac Sodium | 30 | $1,364 |
| Raloxifene Hcl | 16 | $1,073 |
| Tamoxifen Citrate | 22 | $895 |
| Hydroxyurea | 20 | $632 |
| Anastrozole | 29 | $550 |
| Gabapentin | 38 | $455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $1,943 | $322,50223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Philadelphia
- Henry FungPhiladelphia$730K
- Charu AggarwalPhiladelphia$541K
- Corey LangerPhiladelphia$492K
- Ankur ParikhPhiladelphia$329K
- Catherine LaiPhiladelphia$281K
- Stephen SchusterPhiladelphia$218K
- Keith PratzPhiladelphia$173K
- David PorterPhiladelphia$140K
- Adam BinderPhiladelphia$136K
- Marcela MausPhiladelphia$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.